Pioneering in vivo gene editing
Cellectis (cellectis.com) scores 81 out of 100 on Brand Analyzer, placing it in the Strong Brand tier among Healthcare brands, in the 81st percentile of 19324 Healthcare brands.
Cellectis is a biopharmaceutical company founded in 1999 and headquartered in France. The company focuses on in vivo gene editing, aiming to develop a new generation of genetic medicines through what it terms 'gene surgery.' Using proprietary TALEN, TALEB, and TALEM genome engineering platforms, Cellectis edits, rewrites, and reprograms genes directly within the body, moving beyond ex vivo disease management toward addressing the root causes of genetic diseases such as dyslipidemia.
| Brand Name | Cellectis |
|---|---|
| Domain | cellectis.com |
| Industry | Healthcare |
| Founded | 1999 |
| Headquarters | France |
| Main Competitors | Intellia Therapeutics (84/100), CRISPR Therapeutics (79/100), Editas Medicine (82/100), Beam Therapeutics (76/100), Precision BioSciences (76/100), Sangamo Therapeutics (84/100), Verve Therapeutics (74/100), Caribou Biosciences (76/100) |
Moz Domain Authority 52/100 vs category average 40 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #619,921 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Cellectis is pioneering gene surgery through in vivo gene editing technologies to create a new generation of genetic medicines." (Meta description: 19 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Apache, WordPress.
Social footprint: verified profiles on X (Twitter), LinkedIn, Facebook, Instagram, YouTube; no detected presence on GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Cellectis?", Claude could identify the brand as of October 2026. Cellectis is a French biopharmaceutical company that pioneers gene-editing technology, specifically TALEN (transcription activator-like effector nuclease), to develop allogeneic CAR-T cell therapies for cancer treatment. It's known for creating off-the-shelf, donor-derived immuno Best known for Developing TALEN gene-editing technology for off-the-shelf allogeneic CAR-T cancer immunotherapies.
When asked "Best brands similar to Cellectis?", Claude would recommend Cellectis as of October 2026. It's a legitimate and recognized pioneer in allogeneic CAR-T and gene editing, so it would come up naturally in discussions of cell therapy or gene-editing biotech companies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Cellectis's main competitors in Healthcare: Intellia Therapeutics (84/100), CRISPR Therapeutics (79/100), Editas Medicine (82/100), Beam Therapeutics (76/100), Precision BioSciences (76/100).
Sources: Brand Analyzer scan
Cellectis offers in vivo gene editing technologies built on its proprietary TALEN, TALEB, and TALEM genome engineering platforms. These technologies are used to edit, rewrite, and reprogram genes directly within the body to develop genetic medicines targeting diseases such as dyslipidemia.
Sources: Cellectis official site
Cellectis is a biopharmaceutical company founded in 1999 and headquartered in France. It specializes in in vivo gene editing technologies, described by the company as 'gene surgery,' aimed at developing a new generation of genetic medicines.
Sources: Cellectis official site
Cellectis has limited AI-search visibility, scoring 41/100 on Brand Analyzer's AI visibility composite (visibility 28, trust 46, recommendation 58). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Cellectis official site
Cellectis was founded in 1999. Cellectis operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Cellectis is headquartered in France. Cellectis operates in the Healthcare category.
Sources: Wikidata
Cellectis develops in vivo gene editing technologies that allow genes to be edited, rewritten, and reprogrammed directly within the body. Using its proprietary TALEN, TALEB, and TALEM genome engineering platforms, the company works to create genetic medicines intended to address the root causes of genetic diseases rather than just managing symptoms.
Sources: Cellectis official site
Cellectis scores 58/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Cellectis official site
Cellectis is known for its proprietary TALEN, TALEB, and TALEM genome engineering platforms, which it uses to perform in vivo gene editing, or 'gene surgery.' The company is recognized for shifting the gene therapy field from ex vivo approaches toward direct in vivo editing aimed at providing lasting therapeutic solutions for genetic diseases.
Sources: Cellectis official site
Cellectis can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Cellectis official site
Cellectis's technologies and partnerships are intended for biopharmaceutical partners, researchers, and patients affected by genetic diseases such as dyslipidemia who require lasting, curative genetic medicine solutions.
Sources: Cellectis official site
Cellectis scores 41/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Cellectis has a limited AI-visibility profile at 41/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (58/100) and its weakest is visibility (28/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #619,921 (Tranco) and a Moz Domain Authority of 52/100. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Cellectis from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Cellectis: Center for Environmental Health (81/100), Cegedim (81/100), Center for Vein Restoration (81/100), Centerstone (81/100).
A step up - brands to learn from: Zoetis (91/100), theSkimm (91/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.